Table 3.
Clinical and demographic characteristics of the study participants with trait anxiety symptoms, compared to those without trait anxiety symptoms and healthy controls.
| Total cohort (n = 198) |
Trait anxiety (n = 81) |
Trait anxiety ctrls (n = 117) |
Healthy controls (n = 106) |
Trait anxiety vs Trait anxiety ctrls |
State anxiety vs healthy controls |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mean±SD |
mean±SD |
mean±SD |
mean±SD |
||||||||||||
| median |
(IQR) |
median(IQR) |
median(IQR) |
median(IQR) |
|||||||||||
| n (%) | n (%) | n (%) | n (%) | p-value | p-value | ||||||||||
| Age | 37.0 | (30.0– 43.0) | 37.0 | (29.0– 41.0) | 38.0 | (30.0– 44.0) | 38 | (30– 44) | NS | NS | |||||
| Female | 139 (70%) | 62 | (77%) | 77 | (66%) | 71 (67%) | NS | NS | |||||||
| Weight | 65.0 | (56.3– 73.0) | 63.0 | (56.0– 72.0) | 65.0 | (57.0– 74.0) | 65 | (57– 73) | NS | NS | |||||
| BMI | 22.9 | (20.7– 24.9) | 22.8 | (20.3– 24.9) | 23.0 | (32.3– 24.8) | 23.02 | (21– 25) | NS | NS | |||||
| Autoimmune disease ever | 24 (12%) | 9 (11%) | 15 (13%) | 14 (13%) | NS | NS | |||||||||
| IBD IB coeliacs ever | 33.0 (17%) | 8.0 (10%) | 25.0 (21%) | 21 (20%) | 0.052 | NS | |||||||||
| Periodontitis ever | 44 (22%) | 20 (25%) | 24 (21%) | 22 (21%) | NS | NS | |||||||||
| Time since COVID diag months | 8.1 ±4.30 | 6.2 ±3.87 | 9.1 ±4.24 | 2 | (1– 3) | < 0.05 | < 0.05 | ||||||||
| Psych meds ever | 58 (29%) | 31 (38%) | 27 (23%) | 21 (20%) | < 0.05 | < 0.01 | |||||||||
| CTQ total | 31.0 | (27.0– 39.0) | 35.0 | (30.0– 41.0) | 29.0 | (27.0– 35.0) | 29 | (27– 34) | <0.001 | < 0.001 | |||||
| WHOQOL | |||||||||||||||
| DOM1 | 15.4 | (13.7– 17.1) | 13.9 ±2.46 | 16.6 | (14.9– 17.7) | 16.57 | (15– 18) | <0.001 | < 0.001 | ||||||
| DOM2 | 14.0 | (12.0– 16.0) | 12.0 ±2.27 | 15.4±1.99 | 15.55 ±2 | <0.001 | NS | ||||||||
| DOM3 | 13.3 | (10.7– 16.0) | 11.7 ±3.14 | 14.7 | (12.0– 17.3) | 14.67 | (12– 17) | <0.001 | < 0.001 | ||||||
| DOM4 | 15.5 | (14.0– 17.0) | 14.1 ±2.35 | 16.0 | (15.0– 17.5) | 16.3 ±2 | <0.001 | < 0.001 | |||||||
| OV QOL GH | 7.0 | (6.0– 8.0) | 7.0 | (5.0– 7.0) | 8.0 | (7.0– 9.0) | 8 | (7– 9) | <0.001 | < 0.001 | |||||
| PCL Total | 10.0 | (9.0– 12.0) | 22.0 | (6.0– 35.8) | 6.0 | (2.0– 14.0) | 5 | (2– 14) | <0.001 | < 0.001 | |||||
| PTSD symptoms | 16 (8%) | 16 | (20%) | 0 | 0 | <0.001 | < 0.001 | ||||||||
| CESD Total | 10.0 | (5.0– 19.0) | 22.0 | (13.0– 32.0) | 6.0 | (3.0– 10.0) | 6 | (3– 10) | <0.001 | < 0.001 | |||||
| Depressive symptoms | 32 (16%) | 32 (40%) | 0 (0%) | 0 (0%) | <0.001 | < 0.001 | |||||||||
| STAI | |||||||||||||||
| State Total | 38.0 | (31.0– 46.8) | 48.4 ±9.03 | 32.8 ±6.76 | 32 | (27– 36) | <0.001 | < 0.001 | |||||||
| Trait Total | 42.0 | (35.0– 51.0) | 53.0 | (49.0– 58.0) | 37.0 | (33.0– 41.0) | 36 | (33– 41) | <0.001 | < 0.001 | |||||
| State anxiety symptoms | 74 (37%) | 63(78%) | 11 (9%) | 0 (0%) | <0.001 | < 0.001 | |||||||||